Idaho to use one drug in executions

Todd Dvorak Associated Press

BOISE – Idaho’s executioners will use one drug to carry out a lethal injection scheduled next month, bringing the state in line with other death penalty states switching from a three-drug mixture, the state’s corrections chief said Friday.

The state execution team will administer a single, lethal dose of the surgical sedative pentobarbital during the scheduled June 12 execution of convicted murderer Richard Leavitt, said Brent Reinke, director of the Department of Corrections.

His decision marks a departure from Idaho’s most recent execution in November, when a mixture of three chemicals, including pentobarbital, was used to execute Paul Ezra Rhoades in the state’s first execution in 17 years.

Reinke said the single-dose injection complies with the newest version of the state’s execution policy, which also allows the state the options of returning to the three-drug mixture later.

The switch was also driven in part by the difficulty of obtaining the other two drugs that were used on Rhoades. Pentobarbital is an anesthetic used to put condemned inmates to sleep before other lethal drugs are administered, but it is lethal in higher doses.

Arizona, Ohio, Texas and several other states made the switch to pentobarbital last year.

Thank you for visiting Spokesman.com. To continue reading this story and enjoying our local journalism please subscribe or log in.

You have reached your article limit for this month.

Subscribe now and enjoy unlimited digital access to Spokesman.com

Unlimited Digital Access

Stay connected to Spokane for as little as 99¢!

Subscribe for access

Already a Spokesman-Review subscriber? Activate or Log in

You have reached your article limit for this month.

Subscribe now and enjoy unlimited digital access to Spokesman.com

Unlimited Digital Access

Stay connected to Spokane for as little as 99¢!

Subscribe for access

Already a Spokesman-Review subscriber? Activate or Log in

Oops, it appears there has been a technical problem. To access this content as intended, please try reloading the page or returning at a later time. Already a Spokesman-Review subscriber? Activate or Log in